ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD · NASDAQ Global Select
-$0.13 today
Vol 3.23M · Avg 1.66M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ACAD · Revenue to Net Income
Key Ratios
Analysis
$1.1B of revenue converted into $375.6M of net income for the selected period. Gross margin is 91.5% and net margin is 33.4%, showing how much revenue survives after costs and taxes. EPS is $2.20, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B +11.9% | $957.8M +31.8% | $726.4M +40.4% | $517.2M +6.8% | $484.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $89.0M +8.7% | $81.8M +79.0% | $45.7M +349.8% | $10.2M -46.9% | $19.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $982.5M +12.2% | $876.0M +28.7% | $680.7M +34.2% | $507.1M +9.0% | $465.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 91.7% +0.2pp | 91.5% -2.2pp | 93.7% -4.3pp | 98.0% +2.0pp | 96.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $328.8M +8.4% | $303.2M -13.8% | $351.6M -2.8% | $361.6M +51.0% | $239.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $548.9M +12.4% | $488.4M +21.4% | $402.5M +9.0% | $369.1M -6.8% | $396.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $877.7M +36.0% | $645.2M -14.4% | $754.1M +3.2% | $730.7M +15.0% | $635.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $11.8M -26.0% | $15.9M +186.1% | $5.6M +174.0% | $2.0M -39.4% | $3.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | $150.7M +50.4% | $100.2M +320.2% | -$45.5M +78.5% | -$211.4M -28.8% | -$164.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 14.1% +3.6pp | 10.5% +16.7pp | -6.3% +34.6pp | -40.9% -7.0pp | -33.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | $104.8M -54.6% | $230.8M +414.5% | -$73.4M +67.2% | -$223.6M -31.2% | -$170.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 9.8% -14.3pp | 24.1% +34.2pp | -10.1% +33.1pp | -43.2% -8.0pp | -35.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $31.7M +24.6% | $25.5M +47.7% | $17.2M +160.7% | $6.6M +1018.4% | $591.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $34.1M +25.0% | $27.3M +22.1% | $22.3M +120.1% | $10.2M +247.7% | $2.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $138.9M -46.2% | $258.1M +605.7% | -$51.0M +76.1% | -$213.4M -27.4% | -$167.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 13.0% -14.0pp | 26.9% +34.0pp | -7.0% +34.2pp | -41.3% -6.7pp | -34.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$252.1M -897.2% | $31.6M +208.5% | $10.3M +305.0% | $2.5M +621.1% | $351.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $391.0M +72.7% | $226.5M +469.5% | -$61.3M +71.6% | -$216.0M -28.7% | -$167.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | 36.5% +12.8pp | 23.6% +32.1pp | -8.4% +33.3pp | -41.8% -7.1pp | -34.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +69.3% | $1 +470.3% | -$0 +72.4% | -$1 -27.6% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +68.4% | $1 +467.6% | -$0 +72.4% | -$1 -27.6% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $169.3M +2.2% | $165.7M +1.2% | $163.8M +1.3% | $161.7M +0.7% | $160.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $171.4M +3.0% | $166.4M +1.6% | $163.8M +1.3% | $161.7M +0.7% | $160.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Immunovant, Inc.
NASDAQ:IMVT
$7.19B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.90B
Belite Bio, Inc
NASDAQ:BLTE
$5.88B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.37B
Mirum Pharmaceuticals, Inc.
NASDAQ:MIRM
$5.27B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.75B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.56B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.25B
Soleno Therapeutics, Inc.
SLNO
$2.76B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.96B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ACAD generate?
ACADIA Pharmaceuticals Inc. (ACAD) reported $1.07B of revenue in fiscal 2025.
Is ACAD profitable?
ACADIA Pharmaceuticals Inc. (ACAD) reported $391.00M of net income, with a net margin of 36.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.